“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools and services for cell and gene therapies, announced its recently acquired SciSafe division has been awarded a two year contract from a large pharmaceutical company for cold chain management and storage of COVID-19 vaccines. The contract value is approximately $2.7 million.
Mike Rice, BioLife CEO, commented, “Garrie Richardson, former SciSafe CEO and now General Manager, Biologic Storage Services at BioLife, has built a great business and it’s clear SciSafe’s scalable and high quality operations are driving interest from leading pharma companies. We are actively engaged in presenting SciSafe services to our marquee cell and gene therapy customers.”
Management estimates that SciSafe will contribute approximately $9 million in incremental revenue in 2021.